Navigation Links
BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life'

FREDERICK, Md., July 7 /PRNewswire-FirstCall/ -- ActiPatch(TM), the product marketed by Bioelectronics Corp. (Pink Sheets: BIEL), is changing the face of medicine and the way we heal. Recently chosen as "One of 9 Medical Breakthroughs That May Change Your Life," by, ActiPatch is fast becoming the treatment of choice for everything from soft tissue injuries to surgical recovery.

"The decision to include ActiPatch in the top 9 medical breakthroughs was an easy one," said Reginald Saxton, President of Medical Headway. "ActiPatch fills the void created by consumers who would rather not take pain medications and are seeking safe and effective alternative treatment options," Saxton added, "I knew our readers would be very interested in this product for that reason".

ActiPatch is a drug-free wafer thin patch with an embedded battery operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, home use method that reduces soft tissue pain and swelling, and accelerates healing.

When using ActiPatch, bruises that would normally take three weeks to heal often heal in a week; ankle sprains usually respond positively with reduced pain and swelling in only a single day; plastic surgery incisions that would normally take weeks to heal typically heal in less than a week. These claims are supported by multiple clinical trials and strong endorsements from leading surgeons and physicians.

BioElectronics has already received FDA clearance for one surgical procedure, (blepharoplasty), and is now able to sell the product within the United States through physician referral. In addition, BioElectronics has received blanket approval in the European Union, Canada, and dozens of countries. These international approvals have allowed the product to be placed in stores for over-the-counter purchase outside the United States.

Andrew J. Whelan, CEO of BioElectronics Corporation, explains, "ActiPatch with its non-invasive, very efficient treatment for swelling and pain while accelerating recovery is the medicine of the future available today. We are actively pursuing additional reimbursement approvals nationally. ActiPatch is an important product that not only works without side-effects, it also has the potential to help keep medical costs down at a time when they appear to be spiraling out of control," adds Whelan. is an online medical breakthrough library published by Medical Headway, LLC of Houston, TX. Dedicated to arming the public with news of the latest breakthroughs in the world of medicine, the company offers consumers free and complete access to its growing library of cutting-edge, professional medical treatment and product information. "In our opinion, ActiPatch is a huge advance for millions of people who would rather not take a pill or who need faster pain relief ... a clear breakthrough everyone should know about," explains Saxton.

For more information visit or call 866-757-2284.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

Information on ActiPatch and BioElectronics Corporation is available at the following websites:

-- U.S. Consumer:

-- Podiatry:

-- Plastic Surgery: and

-- German orthopedic foot & ankle:

-- Italy and Switzerland:

-- Canada:

-- Netherlands:

-- Singapore & Malaysia:

-- BioElectronics Corp:

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Relations Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email:

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email:

SOURCE Bioelectronics Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
2. BioElectronics Announces Conference Call to Update Investors on Growth Initiatives
3. BioElectronics Corporation Receives Major Orders From Italian Distributor
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. BioElectronics Announces Canadian Retail Product Launch
6. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
9. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
10. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
11. Neogen Acquires Product Line From DuPont Animal Health Solutions
Post Your Comments:
(Date:10/13/2015)... SPRINGS, Florida , October 13, 2015 ... AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ), and ... ARRY ), Avanex Life Sciences Corp. (OTCQX: AVXLD), ... Pharmaceuticals, Inc. (NASDAQ: PGNX ) --> ... and the biotech industry can potentially lead to advancements ...
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
(Date:10/13/2015)... ... ... Proove Biosciences, a commercial and research leader ... Medicine of the University of Southern California (USC) Pain Center to study ... Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one of ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
Breaking Biology Technology:
(Date:10/12/2015)... 9, 2015 Research and Markets ( ... new report "Biometrics: Market Shares, Strategies, and Forecasts, ... --> --> The study is ... market segment. Research represents a selection from the mountains ... market materials, with selections made by the most senior ...
(Date:10/8/2015)... Calif. , Oct. 8, 2015 ... of human interface solutions, announced today that it ... of fiscal 2016 on Thursday, October 22, 2015, ... host a corresponding conference call for analysts and ... during which management may discuss forward-looking information.    ...
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
Breaking Biology News(10 mins):